Insight & Intelligence

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

May 01, 2011 (Vol. 31, No. 9)

New Macrolides Essential to Treat CABP

Community-Acquired Bacterial Pneumonia and Other Infections Must Be Addressed Now

  • Increased rates of resistance of Streptococcus pneumoniae to currently available macrolides such as azithromycin and clarithromycin have increased the challenges of treating community-acquired bacterial pneumonia (CABP). In addition, despite the decrease in pneumococcal disease in infants and young children due to the introduction of pneumococcal conjugate vaccines, the prevalence ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.

Be sure to take the GEN Poll

{{ vm.poll.Title }}

More »